WO2005115547A3 - Myricitrin compounds for sleeping disorders - Google Patents

Myricitrin compounds for sleeping disorders Download PDF

Info

Publication number
WO2005115547A3
WO2005115547A3 PCT/US2005/016783 US2005016783W WO2005115547A3 WO 2005115547 A3 WO2005115547 A3 WO 2005115547A3 US 2005016783 W US2005016783 W US 2005016783W WO 2005115547 A3 WO2005115547 A3 WO 2005115547A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
myricitrin
sleeping disorders
composition
disorder
Prior art date
Application number
PCT/US2005/016783
Other languages
French (fr)
Other versions
WO2005115547A2 (en
Inventor
Hsiao Chang Chan
Yu Lin Gou
Dewi Kenneth Rowlands
Yiu Wa Chung
Original Assignee
Bright Future Pharmaceutical L
Hsiao Chang Chan
Yu Lin Gou
Dewi Kenneth Rowlands
Yiu Wa Chung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bright Future Pharmaceutical L, Hsiao Chang Chan, Yu Lin Gou, Dewi Kenneth Rowlands, Yiu Wa Chung filed Critical Bright Future Pharmaceutical L
Priority to JP2007527316A priority Critical patent/JP2007538078A/en
Priority to CN2005800158156A priority patent/CN101001670B/en
Priority to DE602005026276T priority patent/DE602005026276D1/en
Priority to AT05750345T priority patent/ATE497809T1/en
Priority to EP05750345A priority patent/EP1750808B1/en
Publication of WO2005115547A2 publication Critical patent/WO2005115547A2/en
Publication of WO2005115547A3 publication Critical patent/WO2005115547A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided herein is a composition that contains an effective amount of one or more compounds in particular myricitrin and related compounds for treating, preventing, or ameliorating a disorder such as insomnia or another sleeping disorder and using the composition.
PCT/US2005/016783 2004-05-18 2005-05-13 Myricitrin compounds for sleeping disorders WO2005115547A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2007527316A JP2007538078A (en) 2004-05-18 2005-05-13 Myricitrin compounds for sleep disorders
CN2005800158156A CN101001670B (en) 2004-05-18 2005-05-13 Compositions for sleeping disorders
DE602005026276T DE602005026276D1 (en) 2004-05-18 2005-05-13 MYRICITRINE COMPOUNDS FOR THE TREATMENT OF SLEEP DISORDERS
AT05750345T ATE497809T1 (en) 2004-05-18 2005-05-13 MYRICITRINE COMPOUNDS USED TO TREAT SLEEP DISORDERS
EP05750345A EP1750808B1 (en) 2004-05-18 2005-05-13 Myricitrin compounds for treating sleeping disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57252804P 2004-05-18 2004-05-18
US60/572,528 2004-05-18

Publications (2)

Publication Number Publication Date
WO2005115547A2 WO2005115547A2 (en) 2005-12-08
WO2005115547A3 true WO2005115547A3 (en) 2007-03-08

Family

ID=34993353

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/016783 WO2005115547A2 (en) 2004-05-18 2005-05-13 Myricitrin compounds for sleeping disorders

Country Status (8)

Country Link
US (2) US7935714B2 (en)
EP (1) EP1750808B1 (en)
JP (1) JP2007538078A (en)
KR (1) KR20070020036A (en)
CN (1) CN101001670B (en)
AT (1) ATE497809T1 (en)
DE (1) DE602005026276D1 (en)
WO (1) WO2005115547A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ560633A (en) * 2005-03-11 2011-08-26 Neuprotect Pty Ltd Flavonoid compounds and uses thereof
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
GB0618168D0 (en) * 2006-09-15 2006-10-25 Babraham Inst Compounds
TWI366565B (en) * 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
JP5247667B2 (en) * 2008-12-05 2013-07-24 大塚製薬株式会社 Medicine
JP6100692B2 (en) * 2011-10-06 2017-03-22 ライオン株式会社 Sleep quality improver
CN103381152A (en) * 2013-02-05 2013-11-06 吉林省金梓源生物科技有限公司 Application of myricetin used as cathepsin K inhibitor
JP6564032B2 (en) * 2014-11-14 2019-08-21 ユナイテッド アラブ エミレーツ ユニバーシティＵｎｉｔｅｄ Ａｒａｂ Ｅｍｉｒａｔｅｓ Ｕｎｉｖｅｒｓｉｔｙ Compounds for contrast agents
CN105712966B (en) * 2016-01-22 2018-06-12 梁京 A kind of phenol boheic acid element and its preparation method and application
CN106674216B (en) * 2016-12-21 2019-06-11 贵州大学 A kind of myricetin derivative of the sulfide based structural containing thiadiazoles and preparation method thereof
CN107137391A (en) * 2017-05-23 2017-09-08 苏州大学 Purposes of the dihydromyricetin in terms of the medicine for the treatment of depression is prepared
CN110063952A (en) * 2018-01-22 2019-07-30 山东冠秀生物科技有限公司 Dihydromyricetin derivative improves the purposes in sleep in treatment
EP3643183A1 (en) * 2018-10-26 2020-04-29 Analyticon Discovery GmbH Preparations with c-methyl flavonoids
JP7392219B2 (en) * 2020-01-20 2023-12-06 株式会社萌芽プランツ Flavonoid composition
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
CN117582449A (en) * 2024-01-18 2024-02-23 北京佳福瑞生物科技有限公司 Composite with nervous system regulating effect based on SMART O-ONE technology

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002015901A1 (en) * 2000-08-22 2002-02-28 Neuronex Co., Ltd. Myricetin as an inhibitor of serotonin n-acetyltransferase

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5502047A (en) 1993-03-22 1996-03-26 Kavey; Neil B. Treatment for insomnia
JPH0725761A (en) * 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd Agent for protecting cartilage
JPH0987619A (en) * 1995-09-28 1997-03-31 Sanei Gen F F I Inc Production of antioxidant
US6224872B1 (en) * 1997-07-31 2001-05-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Composition
US20030206895A1 (en) * 1998-11-13 2003-11-06 Sigma-Tau Healthscience S.P.A. Antioxidant composition comprising propionyl L-carnitine and a flavonoid against throm-bosis and atherosclerosis
IT1306722B1 (en) 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CIRCULATORY DYSFUNCTIONS, INCLUDING L-CARNITINE DERIVATIVES AND EXTRACTS OF
US6211229B1 (en) 2000-02-17 2001-04-03 Neil B. Kavey Treatment of transient and short term insomnia
EP1127572A3 (en) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Use of flavones for treating cycloxygenase-2 mediated diseases
US6344487B1 (en) 2000-06-05 2002-02-05 Neil B. Kavey Treatment of insomnia
EP1377286A1 (en) * 2001-02-20 2004-01-07 Randy H. Ziegler Treatment of schizophrenia
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002015901A1 (en) * 2000-08-22 2002-02-28 Neuronex Co., Ltd. Myricetin as an inhibitor of serotonin n-acetyltransferase

Also Published As

Publication number Publication date
CN101001670B (en) 2012-10-03
DE602005026276D1 (en) 2011-03-24
US20090124627A1 (en) 2009-05-14
CN101001670A (en) 2007-07-18
WO2005115547A2 (en) 2005-12-08
ATE497809T1 (en) 2011-02-15
JP2007538078A (en) 2007-12-27
KR20070020036A (en) 2007-02-16
EP1750808B1 (en) 2011-02-09
EP1750808A2 (en) 2007-02-14
US7935714B2 (en) 2011-05-03
US20050261167A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
WO2005115547A3 (en) Myricitrin compounds for sleeping disorders
WO2005012241A3 (en) p-38 KINASE INHIBITORS
WO2005063232A8 (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
MXPA03007960A (en) Compounds and methods for the treatment of urogenital disorders.
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
WO2006116626A3 (en) Methods and compositions for treating pain
WO2006024018A3 (en) Compositions for treating nociceptive pain
IL178390A0 (en) Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
WO2007056124A3 (en) Compounds for modulating trpv3 function
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
WO2006016262A8 (en) Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
HK1096298A1 (en) Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
WO2006055871A3 (en) Treatment for multiple sclerosis
UA84929C2 (en) Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
WO2006116773A3 (en) Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
WO2004087066A3 (en) Hif-1 inhibitors
AU2003268235A1 (en) Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation
ZA200400313B (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
WO2007097810A3 (en) Treatment for antiphospholipid-syndrome-related pregnancy complications
WO2007029063A3 (en) Treatment and/or prevention of pervasive developmental disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020067024012

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580015815.6

Country of ref document: CN

Ref document number: 2007527316

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005750345

Country of ref document: EP

Ref document number: 4645/CHENP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2005750345

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067024012

Country of ref document: KR